Processing

Please wait...

Settings

Settings

1. US20190047966 - NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

Office United States of America
Application Number 16073413
Application Date 27.01.2017
Publication Number 20190047966
Publication Date 14.02.2019
Publication Kind A1
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
70
condensed with carbocyclic rings or ring systems
72
Quinazolines; Hydrogenated quinazolines
86
with hetero atoms directly attached in position 4
94
Nitrogen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
407
Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/183
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
491
Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
044
with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048
the oxygen-containing ring being five-membered
C07D 239/94
C07D 401/04
C07D 401/14
C07D 403/04
C07D 403/14
C07D 405/12
CPC
C07D 239/94
C07D 401/04
C07D 401/14
C07D 403/04
C07D 403/14
C07D 405/12
Applicants MEIJI SEIKA PHARMA CO., LTD.
Inventors Mami ARAI
Takeru YAMAKAWA
Rie NAKAJIMA
Kota MURASAKI
Yoshinari WAKIYAMA
Yuta FUJIWARA
Makoto ISHIKAWA
Tomohisa NINOMIYA
Priority Data 2016-014957 29.01.2016 JP
Title
(EN) NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
Abstract
(EN)

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof:

embedded image

[in the formula (I), A1 represents a methylene group or the like; A2 represents a methylene group or an oxygen atom; A3 represents an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, or a homopiperazinyl group which is optionally substituted with —N(R1)R2, —N(R1)R3, and/or —R3; A4 represents —O—, —S—, —S(O)—, —S(O)2—, or —N(R1)—; A5 represents an optionally substituted C3-10 cycloalkylalkyl group or the like; R4 represents a halogen atom or the like; and n represents an integer of 0 or 1].